Home Pharma China Web Edition Pharma China Archives Online Databases Subscription/Order/Info Event Calendar China Pharma Providers About Us
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor´s Picks
 
 
 
New Round of Negotiation for NRDL Access Begins as Big Pharma Bosses Led Cheers ...
Chief Editor James Shen offers his monthly review of the Chinese healthcare sector with this issue's emphasis on new round of negotiation for NRDL and a mix bag of pharma... (12/3/2019)
   
Yaobili Set to Change China's Pharmaceutical Industry with New Model (12/4/2019)
Why Chinese Biotech Companies Are Not For Faint-Hearted Investors (12/3/2019)
New Round of Negotiation for NRDL Access Begins as Big Pharma Bosses Led Cheers for China at Import Expo (12/3/2019)
China Gives Merck, BMS Cold Shoulder on Reimbursement List as PD-1 Battle Enters New Phase (12/3/2019)
Amgen Striding Ahead in Innovative Medical Solutions (11/29/2019)
Global Drugmakers Strike Deal to Slash Prices in China (11/29/2019)
Expanding into Asia-Pacific: Life Sciences Opportunities and Strategies for Success (11/28/2019)
Can China's Tech Titans Succeed in Healthcare? (11/27/2019)
What Does Chinese Biotech Want from Professional Investors? (11/26/2019)
AmCham: Draft Implementation Regulations of PRC Foreign Investment Law Released (11/22/2019)
Chinese Biotechnology Dominates U.S. Senate Hearing (11/22/2019)
CNIPA Issued Regulations On Collective Patent Examination (11/21/2019)
Guidelines For Patent Examination Amended: Divisional, GUI, Subject Matter, Delayed Examination And So On (11/21/2019)
Xian Janssen: Embrace Better Future with New Solutions (11/19/2019)
Pharmaceutical Innovation in the APAC Region (11/13/2019)
PingAn Good Doctor and Merck Sign Agreem...  (12/9/2019)
Samsung Bioepis Approved to Initiate Pha...  (12/9/2019)
Joinn Bio Raises $60M in Round A Financi...  (12/9/2019)
NHSA issues New Policy for Drug Price Re...  (12/6/2019)
Recent Executive Moves  (12/6/2019)
Innovent Announces First Patient Dosed i...  (12/6/2019)
Amgen's IND for Osteoporosis Drug Romoso...  (12/5/2019)
XiAn Janssen's Application for 2nd Indic...  (12/5/2019)
Interpace Bio Expands Strategic Partners...  (12/5/2019) (free)
AstraZeneca-Merck Lynparza Approved in C...  (12/5/2019)
Bio-Thera's IND for Biosimilar of Stelar...  (12/4/2019)
Additional Indication for Lenvima (Lenva...  (12/4/2019)
NHC Sets Six Major New Goals to Keep AID...  (12/3/2019)
Biotech Startup Alphamab to Raise $230M ...  (12/3/2019)
EOC Pharma Raised $71M in Series C Round...  (12/3/2019) (free)
Pfizer to Absorb Mylan, Creating Global Generic Powerhou...
PhRMA Calls for Trade Deals That Force Countries to Pay ...
IQVIA: Global Pharma to Grow Slower in the Next Five Yea...
Pfizer and GSK Announce JV to Create a Global Consumer H...
Top 25 Global Pharmaceutical Companies by Market Cap 201...
NH Reports Latest Data on Chinese Smoking Cessation Market
NH Reports on Chinese OTC Eye Care Market in MAT 06/2019
Chinese Human Vaccine Market Driven by HBV, Meningococcal, HAV,...
Chinese Non-prescription Drug Sales Set to Reach CNY 250B by 20...
Chinese Import of Medicines Up Only 1.6% in 3Qs/2019
PingAn Good Doctor and Merck Sign Agreement to Explore Integ...
Joinn Bio Raises $60M in Round A Financing
Interpace Bio Expands Strategic Partnership with Genecast in...
AstraZeneca-Merck Lynparza Approved in China for Ovarian Can...
Additional Indication for Lenvima (Lenvatinib) For Different...
NHSA issues New Policy for Drug Price Regulation
NMPA Announces Withdrawal of Additional 68 Certificate R...
NMPA and NHC Jointly Issues the Provisions for Drug Clin...
NMPA Issues Notice on Relevant Matters for Implementatio...
NMPA Issues Implementation Plan for Reform Measures in F...
China Confirms Exploration of Patent Linkage and Term Restor...
China Issues New Document to Step Up IP Protection Thru Incr...
Senate Report Accuses China of Technology Theft
Northeast Pharma under Anti-monopoly Investigation in Liaoni...
CNIPA Issues Administrative Measures on List of Serious Viol...
Nikkei: Japan's Generic Drugmakers Have A China Dependen...
Korea's Growing Reliance on China for API Supply Flagged...
WuXi STA's Jinshan Facility Passes EMA Inspection
Novartis Disposes Suzhou Novartis PharmTech in Changshu ...
FDA Warns Chinese API Producer Yino
Samsung Bioepis Approved to Initiate Phase 3 Trial of Tr...
Innovent Announces First Patient Dosed in Phase I Trial ...
Amgen's IND for Osteoporosis Drug Romosozumab Approved i...
XiAn Janssen's Application for 2nd Indication of Erleada...
Bio-Thera's IND for Biosimilar of Stelara (Ustekinumab) ...
NHC Sets Six Major New Goals to Keep AIDS/AIDS Under Con...
Expanded 4+7 Trial to Add 35 More Drug Products for Nati...
State Council Issues New Centralized Drug Procurement Pu...
Data Overview of the Chinese BMI System in 2018
NHSA and MOHRSS Conclude Negotiations for the NRDL Categ...
Recent Executive Moves
Recent Executive Moves
Recent Executive Moves
Former Deputy CFDA Commissioner Sentenced to 16 Years in P...
Recent Executive Moves
Upcoming Event: Biologics Manufacturing Asia 2020
Upcoming Event: Asia Wellness Expo 2020
Upcoming Event: NanoPharma 2020
Upcoming Event: IDF Congress 2019
Upcoming Event: Phar-East 2020
Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...
WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...
  WiCON Publishes the China Phar...
  WiCON to Hold Pharma China Ann...
  WiCON Publishes the China Phar...
  WiCON Officially Publishes Chi...
  WiCON Officially Publishes Chi...
© Wicon International Group  Support by: www.heightow.com Site map | Contact Us | Links